AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AtomVie-Global

More Like This

PR Newswire associated0

Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

PR Newswire associated0

AtomVie Global Radiopharma Collaborates with RLS & UPPI to Strengthen its Existing U.S. Radiotherapeutic Distribution Network

PR Newswire associated0

AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership

PR Newswire associated0

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

PR Newswire associated0

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591